AMSBIO expanded its portfolio of stable cell lines. The new cell lines express endogenous or recombinant proteins and are available in a ready-to-use format to facilitate research efforts. Using AMSBIO stable cell lines provides an optimized solution for manufacture of therapeutic and diagnostic protein, as well as applications in drug screening, pharmacological research, and toxicological studies. The portfolio of ready-to-use stable cell lines available from AMSBIO includes: Receptors (RAR a, IGF1 Receptor, Motilin Receptor MLNR...); Ion channels (CFTR, Nav1.7, Kv1.5…); Cell signaling (Notch, JNK, NF-κB, ERK…); Phosphodiesterases (aequorin, CNGA2, PDE1B…); Stem cell related (LGR5, OCT4, LIN28); Fluorescent (GFP, RFP, CFP, YFP); TetR; Luciferase; CRE recombinase/reporter; p53 and DNA repair gene knock-down cell lines (PARP1, MUTYH, MSH2, MLH1, XRCC6, BRCA1, NBS1…).

The company also has experience in cell line development and develops demanding custom cell lines for academic, biotechnology and pharmaceutical organizations worldwide. Using a lentiviral system, AMSBIO scientists establish an optimized cell line according to specification. All AMSBIO custom cell lines are designed specifically to meet client specification as well as our own rigorous internal QC criteria.

AMSBIO LLC, 800-987-0985, www.amsbio.com